Maxillary ExpansionNCT06937775
Rapid Maxillary Expansion Related Oxidative Stress and Periodontal Results
A study testing Periodontal measurements (plaque index, gingival index and probing pocket depth scores ), Biochemical Sample Supply (Collection of serum and saliva samples) and Rapid maxillary expansion with Hyrax appliance in people with Maxillary Expansion, run by Recep Tayyip Erdogan University Training and Research Hospital.
Trial summary
The aim of this study was to investigate the effects of rapid maxillary expansion on local and systemic oxidative stress levels. Thirty-five volunteer patients (17 females and 18 males) who needed rapid maxillary expansion will be included in the study. Read more about this study
- Who is it for?
- Ages 11 to 16 years
- Conditions the study is for
- Maxillary Expansion
- What is being tested?
- Periodontal measurements (plaque index, gingival index and probing pocket depth scores ), Biochemical Sample Supply (Collection of serum and saliva samples) and Rapid maxillary expansion with Hyrax appliance
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 35 participants
- Where
- No sites listed yet
- Study dates
- 10 Jan 2016to 10 Aug 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 11 to 16 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Being between 11-15 years of age,
- Having an indication for maxillary expansion due to maxillary stenosis,
- Being highly cooperative, performing adequate oral care,
- Being periodontally healthy,
- Not having cleft lip and/or palate anomalies,
- Not having any systemic disease,
- Not having used any medication including antibiotics and anti-inflammatory drugs in the last 6 months,
- Not being substance addicted and not smoking.
Who cannot join
- Having inadequate oral hygiene
- Being periodontally unhealthy
- Having cleft lip and/or palate anomalies,
- Having any systemic disease,
- Having used any medication including antibiotics and anti-inflammatory drugs in the last 6 months,
- Being substance addicted and not smoking.
About this study
Official title: Rapid Maxillary Expansion Related Sutural and Dentoalveolar Changes Provoke Salivary Oxidative Stress: A Biochemical Study
The aim of this study was to investigate the effects of rapid maxillary expansion on local and systemic oxidative stress levels. Thirty-five volunteer patients (17 females and 18 males) who needed rapid maxillary expansion will be included in the study. Serum and saliva samples will be collected from each patient during four different periods: a week before the treatment (T0), on the day of sutural separation (T1), at the end of the active expansion period (T2), and after the completion of a 3-month retention period (T3). To evaluate the patients' periodontal status, plaque index, gingival index, and probing pocket depth scores will be recorded for each period. 8-hydroxydeoxyguanosine (8-OHdG), total oxidative status (TOS), total antioxidant capacity (TAS), and oxidative stress index (OSI) biomarkers will be evaluated to determine the local and systemic oxidative stress levels.
- Conditions
- Maxillary Expansion
- Being tested
- Periodontal measurements (plaque index, gingival index and probing pocket depth scores ), Biochemical Sample Supply (Collection of serum and saliva samples), Rapid maxillary expansion with Hyrax appliance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Periodontal measurements (plaque index, gingival index and probing pocket depth scores )Other
Plaque index (PI), gingival index (GI) and probed pocket depth (PPD) scores will be recorded at T0, T1, T2 and T3 assessment periods to evaluate the periodontal status and oral care effectiveness of the participants. PPD is the distance between the gingival margin and the sulcus base. Measurements will be made at 6 different sites (mesio-vestibular, vestibular, disto-vestibular, mesio-oral, oral, disto-oral) of each tooth using a Williams periodontal probe (Hu Friedy, Chicago, Illinois, USA). During the measurements, care will be taken to position the probe as parallel as possible to the long axis of the tooth and not to apply excessive force.
Biochemical Sample Supply (Collection of serum and saliva samples)Other
Serum and saliva samples will obtained from all individuals included in the study at T0, T1, T2 and T3 for biochemical analyses.
For standardisation purposes, blood samples will be collected from the antecubital fossa with the patients in a sitting position. After resting for 30 minutes (min) at room temperature, the samples will be centrifuged (4ºC at 3000 rpm for 5 min) and serum samples will be obtained. The samples will be transferred into eppendorf tubes and stored in the freezer (-80ºC) until the study day.
Sampling will be performed early in the morning. Participants will be warned not to consume anything other than water for the last 12 hours and not to brush their teeth that morning. Individuals will be left with their mouths open for 5 min to allow saliva to accumulate at the floor of the mouth. Unstimulated saliva samples accumulated at the floor of the mouth will be collected and transferred to eppendorf tubes.
Rapid maxillary expansion with Hyrax applianceProcedure or surgery
Rapid maxillary expansion (RME) is the most commonly preferred treatment of skeletal jaw stenosis in the transversal direction. Bilateral anchorage is the process of increasing the transversal dimension of the midpalatal suture (sutura palatina media) by applying strong tensile forces in the lateral direction to the dentoalveolar structures of the teeth and/or palatal bone. The primary goal of treatment is to provide orthopedic movement through sutural separation.
| Study group | Role | What they receive |
|---|---|---|
| TO | Other | 1 week before the placement of the Hyrax appliance Receives: Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores ); Other: Biochemical Sample Supply (Collection of serum and saliva samples) |
| T1 | Other | The day of the first clinical observation of sutural opening (5-7 days after activation) Receives: Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores ); Other: Biochemical Sample Supply (Collection of serum and saliva samples); Procedure: Rapid maxillary expansion with Hyrax appliance |
| T2 | Other | The day of completion of active expansion (3-4 weeks) Receives: Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores ); Other: Biochemical Sample Supply (Collection of serum and saliva samples); Procedure: Rapid maxillary expansion with Hyrax appliance |
| T3 | Other | The day of completion of the 3-month reinforcement period Receives: Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores ); Other: Biochemical Sample Supply (Collection of serum and saliva samples); Procedure: Rapid maxillary expansion with Hyrax appliance |
What is being measured
The primary outcome is the main question the study is designed to answer.
Biochemical analyses - 8-OHdG
8-OHdG is the most frequently encountered and best known mutagenicity of more than 20 oxidative base damage products of ROS in DNA. Since it is easily detected in living cells and body fluids, it is the most commonly used oxidative DNA damage marker.
Serum and saliva levels will be measured using a suitable ELISA kit (Cayman Chemical DNA/RNA Oxidative Damage ELISA Kit Item No.589320) according to the manufacturer's instructions. The measurement principle is as follows: It is based on the competition between 8-OHdG from the sample and 8-OHdG-acetylcholinestarase conjugate (8- OHdG Tracer) from the kit for a limited amount of 8-OHdG monoclonal antibody covering the plate well. The colour intensity measured spectrophotometrically at 410 nm is directly proportional to the tracer and inversely proportional to the amount of free 8-OHdG in the sample.
Measured: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)
Biochemical analyses - Oxidative Stress Index (TOS/TAS=OSI)
Total Oxidative Status (TOS) is a current method used to detect lipid peroxidation and oxidative stress. TOS is considered to be a superior method compared to other methods due to the impracticality of measuring different oxidant molecules individually and the inability to fully reflect the interaction of oxidant molecules with each other. Total Antioxidan Status (TAS) is a biochemical parameter obtained as a result of the sum of the antioxidant capacities of all antioxidants in the biological samples examined. Oxidative Stress Index (OSI) is a proportional value obtained by dividing TOS by TAS. It is directly affected by total oxidative and antioxidant status and reveals the final oxidative status in a practical and understandable way.
OSI value was calculated according to the following formula. OSI = TOS (mmol H2O2 Equiv./L) / TAS (mmol Trolox Equiv./L) x 100
Measured: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)
Secondary outcomes (3)
Clinical Periodontal Assessments-plaque index
Plaque index (PI) scores will be recorded at T0, T1, T2 and T3 assessment periods to evaluate the periodontal status and oral care effectiveness of the participants. The amount and thickness of plaque causing gingival inflammation will be determined. The teeth will be dried by spraying light air and isolated. Each tooth will be scored by measuring with a probe from the gingival margin in six areas (mesiobuccal, distobuccal, mesial, distal, oral, vestibule).
Measured: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)
Clinical Periodontal Assessments-gingival index
Gingival index (GI) scores will be recorded at T0, T1, T2 and T3 assessment periods to evaluate the periodontal status of the participants. The periodontal probe will be placed in the gingival sulcus parallel to the long axis of the teeth from the gum edge. Measurements will be made from the area under the teeth and scoring will be done according to the surface characteristics of the gum. The value found will be divided by the number of teeth and the gingival index will be determined for the entire mouth.
Measured: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)
Clinical Periodontal Assessments-probed pocket depth (PPD)
PPD is the distance between the gingival margin and the sulcus base. Measurements will be made at 6 different sites (mesio-vestibular, vestibular, disto-vestibular, mesio-oral, oral, disto-oral) of each tooth using a Williams periodontal probe (Hu Friedy, Chicago, Illinois, USA). During the measurements, care will be taken to position the probe as parallel as possible to the long axis of the tooth and not to apply excessive force.
Measured: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2025
- Study start10 Jan 2016
- Primary completion10 Mar 2016
- Study completion10 Aug 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Maxillary ExpansionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 35 participants (actual)
Sponsor and investigators
- Lead sponsor
- Recep Tayyip Erdogan University Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dilek KARADOĞAN, Recep Tayyip Erdogan University Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06937775
- Sponsor's protocol ID
- BAP 2015/306
- Status last verified
- Apr 2025
- First submitted
- 29 Mar 2025
- Last updated
- 24 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Rapid Maxillary Expansion Related Sutural and Dentoalveolar Changes Provoke Salivary Oxidative Stress: A Biochemical Study
- ClinicalTrials.gov ID
- NCT06937775
- Acronym / sponsor ID
- BAP 2015/306
- Conditions
- Maxillary Expansion
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 35 participants (actual)
- Lead sponsor
- Recep Tayyip Erdogan University Training and Research HospitalUniversity, hospital or other
- Study start
- 10 Jan 2016 (actual)
- Primary completion
- 10 Mar 2016 (actual)
- Study completion
- 10 Aug 2016 (actual)
- First posted
- 22 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study was to investigate the effects of rapid maxillary expansion on local and systemic oxidative stress levels. Thirty-five volunteer patients (17 females and 18 males) who needed rapid maxillary expansion will be included in the study. Serum and saliva samples will be collected from each patient during four different periods: a week before the treatment (T0), on the day of sutural separation (T1), at the end of the active expansion period (T2), and after the completion of a 3-month retention period (T3). To evaluate the patients' periodontal status, plaque index, gingival index, and probing pocket depth scores will be recorded for each period. 8-hydroxydeoxyguanosine (8-OHdG), total oxidative status (TOS), total antioxidant capacity (TAS), and oxidative stress index (OSI) biomarkers will be evaluated to determine the local and systemic oxidative stress levels.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| TO | Other | Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores ), Other: Biochemical Sample Supply (Collection of serum and saliva samples)1 week before the placement of the Hyrax appliance |
| T1 | Other | Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores ), Other: Biochemical Sample Supply (Collection of serum and saliva samples), Procedure: Rapid maxillary expansion with Hyrax applianceThe day of the first clinical observation of sutural opening (5-7 days after activation) |
| T2 | Other | Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores ), Other: Biochemical Sample Supply (Collection of serum and saliva samples), Procedure: Rapid maxillary expansion with Hyrax applianceThe day of completion of active expansion (3-4 weeks) |
| T3 | Other | Other: Periodontal measurements (plaque index, gingival index and probing pocket depth scores ), Other: Biochemical Sample Supply (Collection of serum and saliva samples), Procedure: Rapid maxillary expansion with Hyrax applianceThe day of completion of the 3-month reinforcement period |
Who may qualify
- Ages
- 11 to 16 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (8 listed)
- Being between 11-15 years of age,
- Having an indication for maxillary expansion due to maxillary stenosis,
- Being highly cooperative, performing adequate oral care,
- Being periodontally healthy,
- Not having cleft lip and/or palate anomalies,
Key exclusion criteria (6 listed)
- Having inadequate oral hygiene
- Being periodontally unhealthy
- Having cleft lip and/or palate anomalies,
- Having any systemic disease,
- Having used any medication including antibiotics and anti-inflammatory drugs in the last 6 months,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Periodontal measurements (plaque index, gingival index and probing pocket depth scores )Plaque index (PI), gingival index (GI) and probed pocket depth (PPD) scores will be recorded at T0, T1, T2 and T3 assessment periods to evaluate the periodontal status and oral care effectiveness of the participants. PPD is the distance between the gingival margin and the sulcus base. Measurements will be made at 6 different sites (mesio-vestibular, vestibular, disto-vestibular, mesio-oral, oral, disto-oral) of each tooth using a Williams periodontal probe (Hu Friedy, Chicago, Illinois, USA). During the measurements, care will be taken to position the probe as parallel as possible to the long axis of the tooth and not to apply excessive force. | Other | T1, T2, T3, TO |
| Biochemical Sample Supply (Collection of serum and saliva samples)Serum and saliva samples will obtained from all individuals included in the study at T0, T1, T2 and T3 for biochemical analyses. For standardisation purposes, blood samples will be collected from the antecubital fossa with the patients in a sitting position. After resting for 30 minutes (min) at room temperature, the samples will be centrifuged (4ºC at 3000 rpm for 5 min) and serum samples will be obtained. The samples will be transferred into eppendorf tubes and stored in the freezer (-80ºC) until the study day. Sampling will be performed early in the morning. Participants will be warned not to consume anything other than water for the last 12 hours and not to brush their teeth that morning. Individuals will be left with their mouths open for 5 min to allow saliva to accumulate at the floor of the mouth. Unstimulated saliva samples accumulated at the floor of the mouth will be collected and transferred to eppendorf tubes. | Other | T1, T2, T3, TO |
| Rapid maxillary expansion with Hyrax applianceRapid maxillary expansion (RME) is the most commonly preferred treatment of skeletal jaw stenosis in the transversal direction. Bilateral anchorage is the process of increasing the transversal dimension of the midpalatal suture (sutura palatina media) by applying strong tensile forces in the lateral direction to the dentoalveolar structures of the teeth and/or palatal bone. The primary goal of treatment is to provide orthopedic movement through sutural separation. | Procedure or surgery | T1, T2, T3 |
Primary outcome
Biochemical analyses - 8-OHdG
Time frame: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)
8-OHdG is the most frequently encountered and best known mutagenicity of more than 20 oxidative base damage products of ROS in DNA. Since it is easily detected in living cells and body fluids, it is the most commonly used oxidative DNA damage marker. Serum and saliva levels will be measured using a suitable ELISA kit (Cayman Chemical DNA/RNA Oxidative Damage ELISA Kit Item No.589320) according to the manufacturer's instructions. The measurement principle is as follows: It is based on the competition between 8-OHdG from the sample and 8-OHdG-acetylcholinestarase conjugate (8- OHdG Tracer) from the kit for a limited amount of 8-OHdG monoclonal antibody covering the plate well. The colour intensity measured spectrophotometrically at 410 nm is directly proportional to the tracer and inversely proportional to the amount of free 8-OHdG in the sample.
Biochemical analyses - Oxidative Stress Index (TOS/TAS=OSI)
Time frame: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)
Total Oxidative Status (TOS) is a current method used to detect lipid peroxidation and oxidative stress. TOS is considered to be a superior method compared to other methods due to the impracticality of measuring different oxidant molecules individually and the inability to fully reflect the interaction of oxidant molecules with each other. Total Antioxidan Status (TAS) is a biochemical parameter obtained as a result of the sum of the antioxidant capacities of all antioxidants in the biological samples examined. Oxidative Stress Index (OSI) is a proportional value obtained by dividing TOS by TAS. It is directly affected by total oxidative and antioxidant status and reveals the final oxidative status in a practical and understandable way. OSI value was calculated according to the following formula. OSI = TOS (mmol H2O2 Equiv./L) / TAS (mmol Trolox Equiv./L) x 100
3 secondary outcomes
Clinical Periodontal Assessments-plaque index
Time frame: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)
Clinical Periodontal Assessments-gingival index
Time frame: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)
Clinical Periodontal Assessments-probed pocket depth (PPD)
Time frame: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jul 2025.
Related trials for Maxillary Expansion
Not yet recruitingObservational study
Three-Dimensional Facial Soft Tissue Changes and Clinical Perception Following MARPE
Maxillary Transverse Deficiency
Not yet recruiting
Tooth-Borne (TBA) Versus Hybrid Expanders (HA) in Surgically Assisted Rapid Maxillary Expansion (SARME)
Maxillary Transverse Deficiency
Not yet recruiting
Evaluation of Occlusal Force Following Rapid Maxillary Expansion Assisted by Piezocision in Different Age Groups
Maxillary Transverse Deficiency, Rapid Maxillary Expansion
Recruiting
The Effectiveness of Early Intervention to Correct the Position of PDC:s
Ectopic Tooth Eruption, Palatal Expansion Technique
Active, not recruiting
Comparison of Laboratory-Fabricated and 3D-Printed Rapid Maxillary Expansion Appliances
Maxillary Constriction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Periodontal measurements (plaque index, gingival index and probing pocket depth scores ), Biochemical Sample Supply (Collection of serum and saliva samples) and Rapid maxillary expansion with Hyrax appliance in people with Maxillary Expansion, run by Recep Tayyip Erdogan University Training and Research Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Biochemical analyses - 8-OHdG (time frame: a week before the treatment (T0), 5-7 days after activation (T1), 3rd week (T2), and after the completion of a 3-month retention period (T3)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2025.